Acinetobacter baumannii represents a formidable nosocomial pathogen, largely due to its rapid acquisition of multidrug resistance and its capacity to cause severe infections. This Gram‐negative ...

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging ...

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by ...

Hospital-acquired infections are often hard to treat because the corresponding pathogens become increasingly resistant against antibiotics. The bacterium Acinetobacter baumannii is particularly feared ...

Please provide your email address to receive an email when new articles are posted on . Adding rifampicin to colistin did not improve the 30-day mortality associated with extensively drug-resistant ...

Credit: Innoviva. Xacduro is available as a kit containing a single dose vial of sulbactam 1g and 2 single-dose vials of durlobactam (0.5g in each vial). Xacduro ® (sulbactam for injection; ...

SHANGHAI, Dec. 24, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the ...

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems ...

Researchers discovered an unexpected link between zinc deficiency, the pro-inflammatory cytokine interleukin-13 (IL-13), and Acinetobacter baumannii lung infection and demonstrated that blocking IL-13 ...

Among new compounds that will be available in the next 5 years, doripenem is an interesting new carbapenem that has activity against Gram-negative organisms similar to that of meropenem. Doripenem is ...